Additive effects of CD59 expression in Gal knockout mice in vitro but not in an ex vivo model |
| |
Authors: | Margaret J. Tango Evelyn Safaris Margarita Romanella Atousa Aminian Marina Katerelos Christine Somerwille RIek G. Tearle Martin J. Pearse Anthony J.E d'Apice |
| |
Affiliation: | Immunology Research Centre, St. Vincent's Hospital, Melbourne, Victoria, Australia;Bresagen Limited, Adelaide, SA, Australia |
| |
Abstract: | Abstract: Transgenic expression of the human complement regulatory molecule CD59 in mice and genetic deletion of the major xenoantigen galactose α 1,3 galactose (Gal KO) each resulted in partial protection of spleen cells from lysis by human serum. These protective effects were additive when the two genetic modifications were combined. However, when the effects of these genetic modifications were examined in an ex vivo model in which mouse hearts were perfused with human plasma, it was Gal KO which was the modification which determined protection. CD59 expression alone was not protective and CD59 expression in combination with Gal knockout did not result in a significant additional increase in protection over and above that provided by Gal knockout alone. The likely explanation for this discrepancy between the in vitro and ex vivo data is that the H2-Kb promoter used to drive CD59 expression results I in substantially less expression on endothelium than on spleen cells. |
| |
Keywords: | CD59 Gal KO spleen cells |
|
|